

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

NALDEMEDINE FOR TREATING OPIOID-INDUCED CONSTIPATION, NICE TA651, SEPTEMBER 2020

GREEN - RECOMMENDED FOR RESTRICTED USE - for initiation in Primary, Community or Secondary care and continuation in Primary Care

Name: generic (trade)	What it is	Licensed indications	Decision status	Nice guidance
NALDEMEDINE tablets (Rizmoic®▼)	Laxative, a peripheral opioid receptor antagonist.	Treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.	Final	NICE TA651- recommended

MSEMOC recommendation:

Naldemedine is recommended for treating opioid-induced constipation in accordance with NICE technology appraisal recommendations and [MSE chronic constipation guidelines](#).

[NICE TA651](#) recommendation:

1.1 Naldemedine is recommended, within its marketing authorisation, as an option for treating opioid-induced constipation in adults who have had laxative treatment

The treatment of opioid-induced constipation depends on whether the opioid is the only cause of the constipation (pure opioid-induced constipation) or if there are other contributing factors (mixed aetiology constipation). Treatment may include a peripherally acting mu-opioid receptor antagonist (PAMORA) alone. But, commonly a PAMORA and a conventional laxative are used together. Naldemedine is an oral PAMORA for adults who have had laxative treatment.

For further information please refer to the Mid and South Essex pathway for the management of chronic constipation

NICE do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population). This is because naldemedine is a further treatment option and the overall cost of treatment will be similar to the current treatment options available.

For further information refer to the [Summary of Product Characteristics](#) for naldemedine.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA651: Naldemedine for treating opioid-induced constipation: https://www.nice.org.uk/guidance/ta651
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	December 2020; January 2021
Review Date	December 2025 or sooner if subject to any new updates nationally